Another week, another twist in the turnaround efforts at Novo Nordisk, the maker of the blockbuster Ozempic and Wegovy weight ...

Novo Nordisk (NVO) recruits top healthcare analyst Michael Novod, a long time bull of the company, as head of its investor ...

The overhaul comes after the foundation ousted former chief executive Lars Fruergaard Jørgensen in May, blaming him for an ...

Novo Nordisk's Q3 results hinge on Ozempic and Wegovy sales as demand growth slows amid rivalry, market limits and compounded ...

The chairman of Novo Nordisk and six other independent board members quit on Tuesday after a dispute with the company’s ...

Eli Lilly's rival Novo Nordisk plans to retail both Ozempic and Wegovy in India as diabetes and weight-loss drugs, respectively.| Business News ...

A new analysis finds that the heart-protecting benefits of semaglutide are largely independent of its weight loss effects.

Shares in Novo Nordisk (NOVOB, Financials) declined about 3% in early Wednesday trading after its controlling shareholder, ...

Once-weekly semaglutide 2.4 mg conferred a greater reduction in major adverse cardiovascular events than placebo, regardless ...

US-based pharma giant Eli Lilly’s blockbuster weight-loss drug, Mounjaro, is set to expand its reach across India through a ...

Get the daily news here. Read the essential Danish news and topics of today - in English. Politiken Edition is your window to Denmark.

(Reuters) -London-based telehealth startup SheMed said on Thursday it raised $50 million in a Series A round, valuing the company at $1 billion, as demand for weight-loss drugs Wegovy and Mounjaro ...